Analyst Price Targets — TTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2026 10:30 am | — | Stifel Nicolaus | $12.00 | $6.02 | TheFly | Tetra Technologies price target lowered to $12 from $13 at Stifel |
| September 1, 2026 11:59 am | — | Northland Securities | $10.00 | $6.55 | TheFly | Tetra Technologies price target lowered to $10 from $14 at Northland |
| August 17, 2026 10:50 am | Sara Nik | H.C. Wainwright | $9.00 | $8.55 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD) |
| July 8, 2026 7:47 am | Ryan Deschner | Raymond James | $10.00 | $9.26 | StreetInsider | Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform |
| June 30, 2026 1:32 pm | — | Northland Securities | $14.00 | $11.43 | TheFly | Tetra Technologies price target raised to $14 from $11.50 at Northland |
| January 12, 2026 10:48 am | Stephen Gengaro | Stifel Nicolaus | $13.00 | $9.87 | StreetInsider | TETRA Technologies Inc. (TTI) PT Raised to $13 at Stifel, 'remains a favorite name' |
| December 31, 2025 2:32 pm | — | Northland Securities | $11.50 | $9.44 | TheFly | Tetra Technologies price target raised to $11.50 from $8.50 at Northland |
| October 30, 2025 12:33 pm | Bobby Brooks | Northland Securities | $8.50 | $7.01 | TheFly | Tetra Technologies price target raised to $8.50 from $8 at Northland |
| October 15, 2025 10:53 am | Stephen Gengaro | Stifel Nicolaus | $9.00 | $7.04 | TheFly | Tetra Technologies price target raised to $9 from $6.50 at Stifel |
| September 26, 2025 1:25 pm | — | Northland Securities | $7.00 | $6.02 | TheFly | Tetra Technologies price target raised to $7 from $5.50 at Northland |
Latest News for TTI
Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND")…
SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET.
Valaris (NYSE: VAL - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings. Profitability This table compares Valaris and Tetra Technologies' net
MIND Technology (NASDAQ: MIND - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both small-cap energy companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 9.8% of MIND
San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TTI.
U.S. House Trading
No House trades found for TTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.